Corrigendum to "Development and validation of Ran as a prognostic marker in stage I and stage II primary breast cancer" [Life Sci., 329 (2023) 121964]

Affiliations

• ¹ College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates; Pharmacological and Diagnostic Research Center, Faculty of Pharmacy and Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan. Electronic address: eltanani@rakmhsu.ac.ae.
• ² Institute of Systems, Molecular and Integrative Biology, Cancer and Polio Research Fund Laboratories, School of Biological Sciences, University of Liverpool, Liverpool L69 7ZB, UK.
• ³ Pharmacological and Diagnostic Research Center, Faculty of Pharmacy and Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan.
• ⁴ Ras Al Khaimah Medical and Health Sciences University, United Arab Emirates; Department of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.
• ⁵ Personalised Medicine Centre, School of Medicine, University of Ulster, UK.
• ⁶ Cell Therapy Center, the University of Jordan, Amman 11942, Jordan.
• ⁷ Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, Ulster University, C-TRIC, Altnagelvin Hospital Campus, Glenshane Road, Derry/Londonderry BT47 6SB, UK.
• ⁸ Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
• ⁹ School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, India.
• ¹⁰ Biomaterials and Bioengineering Laboratory, Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, c/Guillem de Castro 94, 46001, Valencia, Spain.
• ¹¹ Lincoln Medical School, University of Lincoln, Brayford Pool Campus, Lincoln LN6 7TS, UK.